In December 2005, Eli Lilly and Organization agreed to plead responsible and spend $36 million in reference to the unlawful marketing on the drug.[264] Revenue Reps had been experienced to market Evista for breast cancer and cardiovascular disease, to prompt or bait thoughts by Physicians, also